BI
FATE icon

BVF Inc’s Fate Therapeutics FATE Stock Holding History

BVF Inc’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-391,386
Closed -$1.27M – 38
2017
Q2 		$1.27M Sell
391,386
-1,553,859
-80% -$5.95M 0.2% 34
2017
Q1 		$8.85M Sell
1,945,245
-1,814,153
-48% -$6.64M 1.51% 19
2016
Q4 		$9.44M Buy
+3,759,398
New +$10.1M 1.9% 15

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BVF Inc's FATE Position: Q3 2017 in Review

BVF Inc sold out of Fate Therapeutics (FATE) in Q3 2017, closing a stake of 391,386 shares — an estimated $1.27M sold.

BVF Inc first reported a position in FATE in Q4 2016 and held it in 3 quarters. The position peaked at $9.44M in Q4 2016. 74 funds tracked by Wall St. Rank hold FATE as of Q3 2017.

  • BVF Inc reported no remaining Fate Therapeutics position as of Q3 2017 after selling out during the quarter.
  • BVF Inc sold 391,386 Fate Therapeutics shares in Q3 2017, an estimated $1.27M.
  • BVF Inc first reported a position in Fate Therapeutics in Q4 2016 and held it in 3 quarters.
  • BVF Inc's Fate Therapeutics position peaked at $9.44M in Q4 2016.
  • 74 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2017.

Based on BVF Inc's 13F filing for Q3 2017, filed 14 Nov 2017.